Trial Profile
A post-marketing study of obeticholic acid in patients with primary biliary cirrhosis
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2023
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions
- 02 Aug 2023 According to an Intercept Pharmaceuticals media release, Intercept remains on track for a planned regulatory submission to the FDA in 2023 in support of fulfilling post-marketing requirements for Ocaliva in PBC. This submission will include data from this study.
- 10 Nov 2014 New trial record